Mylan prevails in breach of contract case against GlaxoSmithKline

27 March 2014

US generics major Mylan (Nasdaq: MYL) reveals that, after a trial in the US District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract law suit against UK pharma giant GlaxoSmithKline (LSE: GSK) relating to paroxetine hydrochloride extended-release tablets, the latter’s once blockbuster antidepressant Paxil.

The jury decided that GSK owes Mylan $106.7 million in damages. Mylan said it is pleased with the jury verdict and intends to seek additional relief to further protect its rights.

Mylan's claims were based on 2007 agreements with GSK relating to Mylan's Abbreviated New Drug Application for paroxetine hydrochloride ER tablets. Under those agreements, Mylan obtained certain intellectual property rights from GSK. Mylan then launched its generic version in May 2008 and, to date, is the only company to have received Food and Drug Administration approval of an Abbreviated New Drug Application for this product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK